↓ Skip to main content

Cannabinoid receptor 1 is a potential drug target for treatment of translocation-positive rhabdomyosarcoma

Overview of attention for article published in Molecular Cancer Therapeutics, July 2009
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • Among the highest-scoring outputs from this source (#28 of 4,087)
  • High Attention Score compared to outputs of the same age (99th percentile)
  • High Attention Score compared to outputs of the same age and source (99th percentile)

Mentioned by

twitter
12 X users
facebook
530 Facebook pages
googleplus
20 Google+ users

Citations

dimensions_citation
46 Dimensions

Readers on

mendeley
67 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Cannabinoid receptor 1 is a potential drug target for treatment of translocation-positive rhabdomyosarcoma
Published in
Molecular Cancer Therapeutics, July 2009
DOI 10.1158/1535-7163.mct-08-1147
Pubmed ID
Authors

Susanne Oesch, Dagmar Walter, Marco Wachtel, Kathya Pretre, Maria Salazar, Manuel Guzmán, Guillermo Velasco, Beat W. Schäfer

Abstract

Gene expression profiling has revealed that the gene coding for cannabinoid receptor 1 (CB1) is highly up-regulated in rhabdomyosarcoma biopsies bearing the typical chromosomal translocations PAX3/FKHR or PAX7/FKHR. Because cannabinoid receptor agonists are capable of reducing proliferation and inducing apoptosis in diverse cancer cells such as glioma, breast cancer, and melanoma, we evaluated whether CB1 is a potential drug target in rhabdomyosarcoma. Our study shows that treatment with the cannabinoid receptor agonists HU210 and Delta(9)-tetrahydrocannabinol lowers the viability of translocation-positive rhabdomyosarcoma cells through the induction of apoptosis. This effect relies on inhibition of AKT signaling and induction of the stress-associated transcription factor p8 because small interfering RNA-mediated down-regulation of p8 rescued cell viability upon cannabinoid treatment. Finally, treatment of xenografts with HU210 led to a significant suppression of tumor growth in vivo. These results support the notion that cannabinoid receptor agonists could represent a novel targeted approach for treatment of translocation-positive rhabdomyosarcoma.

X Demographics

X Demographics

The data shown below were collected from the profiles of 12 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 67 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 2 3%
Switzerland 1 1%
Germany 1 1%
Belgium 1 1%
United States 1 1%
Unknown 61 91%

Demographic breakdown

Readers by professional status Count As %
Researcher 18 27%
Student > Ph. D. Student 14 21%
Student > Bachelor 8 12%
Professor 4 6%
Student > Master 4 6%
Other 11 16%
Unknown 8 12%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 13 19%
Medicine and Dentistry 13 19%
Agricultural and Biological Sciences 13 19%
Engineering 5 7%
Chemistry 3 4%
Other 9 13%
Unknown 11 16%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 161. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 17 November 2023.
All research outputs
#251,901
of 25,381,864 outputs
Outputs from Molecular Cancer Therapeutics
#28
of 4,087 outputs
Outputs of similar age
#574
of 118,578 outputs
Outputs of similar age from Molecular Cancer Therapeutics
#1
of 73 outputs
Altmetric has tracked 25,381,864 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 4,087 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.8. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 118,578 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.
We're also able to compare this research output to 73 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 99% of its contemporaries.